# Clinical Trial Project Charter

## Document Control

| Document Information | Details |
|----------------------|---------|
| Document Title | Clinical Trial Project Charter |
| Protocol Number | [Study Identifier, e.g., ABC-XYZ-123] |
| Version | [e.g., 1.0] |
| Date Issued | [YYYY-MM-DD] |
| Sponsor | [Sponsor Organization Name] |
| Principal Investigator | [Name and Credentials] |
| Project Manager | [Name and Contact] |

### Version History

| Version | Date | Description of Changes | Author | Approved By |
|---------|------|------------------------|--------|------------|
| 0.1 | [YYYY-MM-DD] | Initial draft | [Name] | - |
| 1.0 | [YYYY-MM-DD] | Approved version | [Name] | [Name] |

### Document Approvals

| Role | Name | Signature | Date |
|------|------|-----------|------|
| Sponsor Representative | | | |
| Principal Investigator | | | |
| Medical Monitor | | | |
| Regulatory Affairs | | | |
| Quality Assurance | | | |
| Data Management | | | |
| Project Manager | | | |

---

## 1. Executive Summary

### 1.1 Study Overview
[Provide a concise summary of the clinical trial including the investigational product, therapeutic area, phase, and primary objectives. Limit to 1-2 paragraphs.]

**EXAMPLE:**
*This Phase II randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of ABC-123 in adult patients with moderate to severe rheumatoid arthritis who have had an inadequate response to conventional disease-modifying anti-rheumatic drugs (DMARDs). The study will enroll approximately 200 patients across 25 sites in North America and Europe, with a treatment duration of 24 weeks.*

### 1.2 Business Case
[Describe the unmet medical need this trial addresses and the potential value of the investigational product.]

### 1.3 Strategic Alignment
[Explain how this trial aligns with the organization's therapeutic area strategy and development program.]

---

## 2. Study Information

### 2.1 Study Title
[Full scientific title of the clinical trial as it appears in the protocol.]

### 2.2 Study Phase
[Indicate the phase of clinical development: Phase I, II, III, or IV.]

### 2.3 Study Design
[Briefly describe the study design, including control groups, randomization, blinding, etc.]

**EXAMPLE:**
*This is a randomized, double-blind, placebo-controlled, parallel-group study with a 4-week screening period, 24-week treatment period, and 8-week follow-up period. Subjects will be randomized in a 1:1:1 ratio to receive ABC-123 low dose, ABC-123 high dose, or placebo.*

### 2.4 Investigational Product
| Parameter | Details |
|-----------|---------|
| Name | [Generic and trade name if applicable] |
| Formulation | [e.g., tablet, capsule, injection] |
| Dosage | [Dose levels to be tested] |
| Administration | [Route and frequency] |
| Comparator | [If applicable] |

### 2.5 Study Population
[Describe the target patient population, including key inclusion/exclusion criteria.]

### 2.6 Primary Endpoint
[State the primary outcome measure(s).]

### 2.7 Key Secondary Endpoints
[List the important secondary outcome measures.]

---

## 3. Project Scope

### 3.1 In Scope
- [List all activities that are included in the project scope]

**EXAMPLE:**
- *Protocol development and approval*
- *Site selection, qualification, and initiation*
- *Patient recruitment and enrollment of 200 subjects*
- *Study drug manufacturing, packaging, and distribution*
- *Clinical monitoring and site management*
- *Data management and statistical analysis*
- *Clinical study report preparation*

### 3.2 Out of Scope
- [List activities explicitly excluded from the project scope]

### 3.3 Constraints
- [List factors that limit the project's options]

**EXAMPLE:**
- *Limited availability of comparator drug*
- *Restricted enrollment period due to patent considerations*
- *Specialized equipment requirements at investigational sites*

### 3.4 Assumptions
- [List factors believed to be true for planning purposes]

---

## 4. Regulatory and Compliance Framework

### 4.1 Regulatory Authorities
[List all regulatory authorities to which submissions will be made]

**EXAMPLE:**
- *FDA (United States)*
- *EMA (European Union)*
- *PMDA (Japan)*
- *Health Canada*

### 4.2 Applicable Regulations and Guidelines
[List key regulations and guidelines applicable to this trial]

**EXAMPLE:**
- *ICH E6(R2) Good Clinical Practice*
- *21 CFR Parts 50, 54, 56, and 312*
- *EU Clinical Trials Regulation 536/2014*
- *ICH E8: General Considerations for Clinical Trials*
- *ICH E9: Statistical Principles for Clinical Trials*
- *Local country regulations as applicable*

### 4.3 Ethics Committee/IRB Review
[Describe the approach to ethics committee submissions and approvals]

### 4.4 Required Regulatory Submissions
| Submission | Authority | Target Submission Date | Responsible Party |
|------------|-----------|------------------------|-------------------|
| IND/CTA | [Authority] | [Date] | [Role/Department] |
| Protocol | [Authority] | [Date] | [Role/Department] |
| Annual Reports | [Authority] | [Date] | [Role/Department] |

### 4.5 Compliance Monitoring Plan
[Summarize how regulatory compliance will be monitored throughout the trial]

---

## 5. Patient Safety and Ethical Considerations

### 5.1 Risk Assessment
[Summarize key safety risks to study participants and mitigation strategies]

**EXAMPLE:**
| Risk | Likelihood | Impact | Mitigation Strategy |
|------|------------|--------|---------------------|
| Hepatotoxicity | Medium | High | Liver function monitoring at screening and every 4 weeks |
| Infusion reactions | High | Medium | Pre-medication protocol; emergency response equipment at sites |
| Immunosuppression | Medium | High | Exclusion of subjects with active infections; monitoring for infections |

### 5.2 Data Safety Monitoring
[Describe the data safety monitoring approach, including any committees]

**EXAMPLE:**
*An independent Data Safety Monitoring Board (DSMB) consisting of three physicians with expertise in rheumatology and clinical trials and one biostatistician will review unblinded safety data after 50% of subjects complete 12 weeks of treatment and may recommend protocol modifications or study discontinuation if significant safety concerns arise.*

### 5.3 Safety Reporting Procedures
[Outline the process for adverse event reporting and management]

### 5.4 Subject Informed Consent
[Describe the informed consent process, including special considerations]

### 5.5 Patient Privacy and Confidentiality
[Describe measures to protect patient data and comply with privacy regulations]

**EXAMPLE:**
*All patient data will be de-identified using unique subject identifiers. Personal identifiable information will be stored separately from clinical data with restricted access. Data transfers will be encrypted and comply with HIPAA and GDPR requirements as applicable.*

---

## 6. Clinical Trial Operations

### 6.1 Study Sites

| Parameter | Details |
|-----------|---------|
| Number of Sites | [Planned number] |
| Regions/Countries | [List of countries] |
| Site Selection Criteria | [Key criteria for site selection] |
| First Site Initiation | [Target date] |
| Last Site Initiation | [Target date] |

### 6.2 Patient Recruitment

| Parameter | Details |
|-----------|---------|
| Target Enrollment | [Number of subjects] |
| Screening Ratio | [Expected screen failure rate, e.g., 2:1] |
| First Patient First Visit | [Target date] |
| Last Patient First Visit | [Target date] |
| Last Patient Last Visit | [Target date] |
| Recruitment Rate | [Expected patients/site/month] |
| Recruitment Strategies | [Key strategies to achieve enrollment] |

### 6.3 Study Drug Supply

| Activity | Responsible Party | Timeline |
|----------|-------------------|----------|
| Manufacturing | [Organization/Department] | [Dates] |
| Packaging and Labeling | [Organization/Department] | [Dates] |
| Distribution | [Organization/Department] | [Dates] |
| Accountability | [Organization/Department] | [Process] |
| Return/Destruction | [Organization/Department] | [Process] |

### 6.4 Monitoring Plan
[Summarize the clinical monitoring approach, frequency, and responsible parties]

**EXAMPLE:**
*A risk-based monitoring approach will be implemented with on-site visits every 6-8 weeks and remote monitoring of data between visits. 100% source data verification will be performed for primary endpoint data and safety data, with 20% SDV for other data points.*

### 6.5 Data Management

| Activity | Details | Responsible Party |
|----------|---------|-------------------|
| EDC System | [System name] | [Organization/Department] |
| Database Design | [Approach] | [Organization/Department] |
| Data Entry | [Timeline and process] | [Organization/Department] |
| Medical Coding | [Dictionaries used] | [Organization/Department] |
| Data Validation | [Approach] | [Organization/Department] |
| Database Lock | [Target date] | [Organization/Department] |

### 6.6 Biostatistical Analysis
[Describe the statistical analysis approach, including interim analyses if planned]

---

## 7. Project Timeline

### 7.1 Key Milestones

| Milestone | Target Date | Responsible Party |
|-----------|-------------|-------------------|
| Protocol Approval | [Date] | [Role/Department] |
| First Regulatory Submission | [Date] | [Role/Department] |
| First Site Initiated | [Date] | [Role/Department] |
| First Patient Enrolled | [Date] | [Role/Department] |
| Last Patient Enrolled | [Date] | [Role/Department] |
| Last Patient Last Visit | [Date] | [Role/Department] |
| Database Lock | [Date] | [Role/Department] |
| Clinical Study Report | [Date] | [Role/Department] |

### 7.2 Critical Path
[Identify dependencies that are on the critical path]

### 7.3 Timeline Visualization
[Reference to attached Gantt chart or timeline visualization]

---

## 8. Project Budget and Resources

### 8.1 Budget Summary

| Category | Budgeted Amount | Comments |
|----------|-----------------|----------|
| Clinical Operations | [Amount] | [Details] |
| Investigator Grants | [Amount] | [Details] |
| Study Drug Costs | [Amount] | [Details] |
| Central Lab | [Amount] | [Details] |
| Data Management | [Amount] | [Details] |
| Biostatistics | [Amount] | [Details] |
| Regulatory | [Amount] | [Details] |
| Project Management | [Amount] | [Details] |
| Travel | [Amount] | [Details] |
| Other | [Amount] | [Details] |
| **Total** | **[Total Amount]** | |

### 8.2 Funding Source
[Identify the source of funding for this clinical trial]

### 8.3 Core Project Team

| Role | Name | Organization | Responsibility |
|------|------|--------------|----------------|
| Project Lead | [Name] | [Organization] | [Key responsibilities] |
| Medical Monitor | [Name] | [Organization] | [Key responsibilities] |
| Clinical Operations | [Name] | [Organization] | [Key responsibilities] |
| Biostatistician | [Name] | [Organization] | [Key responsibilities] |
| Data Management | [Name] | [Organization] | [Key responsibilities] |
| Regulatory Affairs | [Name] | [Organization] | [Key responsibilities] |
| Drug Safety | [Name] | [Organization] | [Key responsibilities] |
| Quality Assurance | [Name] | [Organization] | [Key responsibilities] |

### 8.4 Extended Project Team
[List additional team members, vendors, and service providers]

---

## 9. Risk Management

### 9.1 Project Risk Assessment

| Risk | Likelihood | Impact | Risk Score | Mitigation Strategy | Owner |
|------|------------|--------|------------|---------------------|-------|
| [Risk description] | [H/M/L] | [H/M/L] | [Score] | [Strategy] | [Role] |
| [Risk description] | [H/M/L] | [H/M/L] | [Score] | [Strategy] | [Role] |

**EXAMPLE:**
| Risk | Likelihood | Impact | Risk Score | Mitigation Strategy | Owner |
|------|------------|--------|------------|---------------------|-------|
| Slow patient recruitment | High | High | 9 | Increase number of sites; implement patient referral program; engage patient advocacy groups | Clinical Operations |
| Regulatory approval delays | Medium | High | 6 | Pre-submission meetings with authorities; parallel submissions; contingency in timeline | Regulatory Affairs |
| Study drug supply shortage | Low | High | 3 | Manufacture additional batches; extend expiry date studies; staggered site initiation | Supply Chain Manager |

### 9.2 Risk Monitoring and Review
[Describe how risks will be monitored and reviewed throughout the project]

---

## 10. Communication Plan

### 10.1 Internal Communication

| Meeting | Frequency | Participants | Purpose |
|---------|-----------|--------------|---------|
| Core Team Meeting | [e.g., Weekly] | [List roles] | [Purpose] |
| Executive Oversight | [e.g., Monthly] | [List roles] | [Purpose] |
| Vendor Management | [e.g., Biweekly] | [List roles] | [Purpose] |

### 10.2 External Communication

| Stakeholder | Method | Frequency | Responsible |
|-------------|--------|-----------|-------------|
| Regulatory Authorities | [Method] | [Frequency] | [Role] |
| Ethics Committees/IRBs | [Method] | [Frequency] | [Role] |
| Investigators | [Method] | [Frequency] | [Role] |
| Patients/Participants | [Method] | [Frequency] | [Role] |

### 10.3 Escalation Procedures
[Define the process for escalating issues]

---

## 11. Quality Management

### 11.1 Quality Objectives
[State the quality objectives for this clinical trial]

### 11.2 Quality Control Measures
[List quality control activities to be performed]

**EXAMPLE:**
- *100% review of informed consent forms*
- *Source data verification per monitoring plan*
- *Quality control of clinical database*
- *Independent audit of [X]% of sites*
- *Vendor qualification and oversight*

### 11.3 Quality Assurance
[Describe planned audits and inspections]

---

## 12. Project Closure

### 12.1 Closure Requirements
[List all deliverables and activities required for formal project closure]

### 12.2 Archiving Plan
[Describe the approach for archiving essential documents]

### 12.3 Lessons Learned
[Outline the process for capturing and documenting lessons learned]

---

## 13. Approval and Authorization

By signing below, the undersigned acknowledge that they have reviewed this Clinical Trial Project Charter and authorize the project to proceed as described herein.

| Role | Name | Signature | Date |
|------|------|-----------|------|
| Sponsor Representative | | | |
| Chief Medical Officer | | | |
| Head of Clinical Operations | | | |
| Head of Regulatory Affairs | | | |
| Head of Biostatistics & Data Management | | | |
| Project Manager | | | |

---

## Appendices

### Appendix A: Referenced Documents
[List all documents referenced in this charter]

### Appendix B: Glossary
[Define key terms and abbreviations used in this document]

### Appendix C: Detailed Timeline
[Attach or reference detailed project schedule/Gantt chart]

### Appendix D: Budget Details
[Attach or reference detailed budget information]

---

**Note**: This template should be customized for each clinical trial based on phase, therapeutic area, and organizational requirements. All sections should comply with ICH-GCP guidelines and applicable regulatory requirements.

